ET-743: A novel agent with activity in soft tissue sarcomas

Oncologist

Volumn 10, Issue 10, 2005, Pages 827-832

  Fayette, Jérôme ^a,b   Coquard, Isabelle Ray ^a   Alberti, Laurent ^a   Ranchère, Dominique ^a   Boyle, Helen ^a   Blay, Jean Yves ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Cytotoxic; Ecteinascidin 743; First line treatment; Sarcoma

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; IFOSFAMIDE; PACLITAXEL; TRABECTEDIN; VANCOMYCIN;

ALKYLATION; AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT RUPTURE; BONE MARROW SUPPRESSION; CELL CYCLE G2 PHASE; CELL SURVIVAL; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DNA BINDING; DNA REPAIR; DRUG MEGADOSE; DRUG RESPONSE; DRUG STABILITY; EXCISION REPAIR; GENETIC CODE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; LEIOMYOMA; LIVER CELL; LIVER HEMORRHAGE; LIVER NECROSIS; LIVER TOXICITY; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SARCOMA CELL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

EID: 31444456167     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.10-10-827     Document Type: Review

References (45)

1. Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-711.
2. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003;39:64-69.
3. Pommier Y, Kohlhagen G, Bailly C et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-13309.
4. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42: 2493-2497.
5. Bonfanti M, La Valle E, Fernandez Sousa Faro JM et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999;14:179-186.
6. Minuzzo M, Marchini S, Broggini M et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-6784.
7. Jin S, Gorfajn B, Faircloth G et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 2000;97:6775-6779.
8. Kanzaki A, Takebayashi Y, Ren XQ et al. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 2002;1:1327-1334.
9. Friedman D, Hu Z, Kolb EA et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-3381.
10. Takebayashi Y, Pourquier P, Yoshida A et al. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci U S A 1999;96:7196-7201.
11. Damia G, Silvestri S, Carrassa L et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-588.
12. Takebayashi Y, Goldwasser F, Urasaki Y et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001;7:185-191.
13. Erba E, Bergamaschi D, Bassano L et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105.
14. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-966.
15. Zewail-Foote M, Li VS, Kohn H et al. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001;8: 1033-1049.
16. Soares DG, Poletto NP, Bonatto D et al. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 2005;70: 59-69.
17. Li WW, Takahashi N, Jhanwar S et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-2911.
18. Biroccio A, Gabellini C, Amodei S et al. Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells. Mol Pharmacol 2003;63:632-638.
19. Marchini S, Marrazzo E, Bonomi R et al. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 2005;41:323-333.
20. Martinez N, Sanchez-Beato M, Carnero A et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005;4:814-823.
21. Shao L, Kasanov J, Hornicek FJ et al. Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 2003;66:2381-2395.
22. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22: 1480-1490.
23. Blay JY, Le Cesne A, Verweij J et al. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2004;40:1327-1331.
24. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584.
25. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-5492.
26. Schöffski P, Huygh G, Clement P et al. Tumor control and objective responses: single-center experience with Ecteinascidin-743 (ET-743, Yondelis), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas. Proc ASCO 2005; 23:9027a.
27. Donald S, Verschoyle RD, Edwards R et al. Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer Res 2002;62:4256-4262.
28. Puchalski TA, Ryan DP, Garcia-Carbonero R et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002;50:309-319.
29. Donald S, Verschoyle RD, Greaves P et al. Complete protection by highdose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003;63:5902-5908.
30. Donald S, Verschoyle RD, Greaves P et al. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother Pharmacol 2004;53:305-312.
31. Donald S, Verschoyle RD, Greaves P et al. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer 2004;111:961-967.
32. Albella B, Faircloth G, Lopez-Lazaro L et al. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer 2002;38:1395-1404.
33. Gomez SG, Bueren JA, Faircloth GT et al. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 2003;31:1104-1111.
34. Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964-2971.
35. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899.
36. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.
37. Samuels BL, Rushing D, Chawla SP et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy. Proc ASCO 2004;22:9000a.
38. Laverdiere C, Kolb EA, Supko JG et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-840.
39. Scotlandi K, Perdichizzi S, Manara MC et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002;8:3893-3903.
40. D'Incalci M, Colombo T, Ubezio P et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003;39:1920-1926.
41. Grasselli G, Malossi A, Colombo N et al. Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. Proc ASCO 2003;22:542a.
42. Meco D, Colombo T, Ubezio P et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-138.
43. Takahashi N, Li WW, Banerjee D et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7: 3251-3257.
44. Morioka H, Weissbach L, Vogel T et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003;9:1211-1217.
45. Simoens C, Korst AE, De Pooter CM et al. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 2003;89:2305-2311.